Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?

Reply to Letter from Drs. Haider and Ashraf

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Current Status of Stem Cell Therapy in Heart Failure

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury

Stem cell therapy for cardiac repair: benefits and barriers

Mesenchymal stem cell therapy for heart disease

Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease

Current Optimized Strategies for Stem Cell-Derived Extracellular Vesicle/exosomes in Cardiac Repair.

Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction

Cardiac Cell Therapy: Insights into the Mechanisms of Tissue Repair

Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells

Abstract 248: Comparison Of Transplantation Of Bone Marrow-derived Stem Cells, Adipose-derived Stem Cells And Endometrium- Derived Stem Cells In The Infarcted Heart

Application of Adipose-Derived Stem Cells in Heart Disease.

Stem cell therapy for heart failure: Medical breakthrough, or dead end?

Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy

Treatment of Heart Failure after Myocardial Infarction with Bone Marrow-derived Mesenchymal Stem Cells

STEM CELL PLASTICITY: REGENERATION OF FUNCTIONAL MYOCARDIUM FROM BONE MARROW STEM CELLS (BMSC).

Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction

Stem cell therapy for cardiac regeneration: past, present, and future